ArticleGynecology and pelvic medicine2026

Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies.

Teresa Zumarraga-Lizundia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.